PDCD1 and neoplasm: Immune checkpoint inhibitors directed against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) on T-cells, facilitate immune recognition of tumor neo-antigens and immune-mediated tumor control [1,2,3,4].